Cybin Inc

Cybin Inc., doing business as Helus Pharma, is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs) as potential treatments for psychiatric and neurological conditions including major depressive disorder (MDD), generalized anxiety disorder (GAD), and alcohol use disorder. The company's lead program, HLP003, is an orally delivered deuterated psilocin molecule that has received FDA Breakthrough Therapy Designation for the potential adjunctive treatment of MDD and is currently in a multinational Phase 3 pivotal program (PARADIGM) comprising three studies: APPROACH, EMBRACE, and EXTEND. Its second program, HLP004, is a deuterated version of DMT being developed as an intramuscular treatment for GAD, with Phase 2 topline results already reported. A third preclinical program, HLP005, focuses on phenethylamine and tryptamine derivatives targeting various psychiatric and neurological indications. The company holds over 100 granted patents and over 250 pending applications across dozens of jurisdictions globally, operates a DEA Schedule I manufacturing-licensed research lab in the Boston area, and has developed the EMBARK psychological support model for use alongside its pharmacological interventions. HLP003 and HLP004 are classified as Schedule I controlled substances in the U.S. and equivalent restricted classifications in Canada, the UK, the EU, and Australia, requiring special regulatory licenses for research and eventual rescheduling for commercialization. The company has six wholly-owned subsidiaries with operations spanning the U.S., Canada, Ireland, the UK, and other jurisdictions. Its common shares trade on Nasdaq and Cboe Canada under the symbol HELP. Updated Aug 14, 2026